SEATTLE--(BUSINESS WIRE)--BEAT BioTherapeutics Corporation (BEATBio) announced today that co-founder and Scientific Advisory Board member Dr. Michael Regnier will present at the upcoming American Society for Gene and Cell Therapy annual meeting on May 4, 2016, in Washington, DC. Dr. Regnier’s presentation is titled “AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility via Myosin Activation.”
